Asterand Subsidiary to Screen Amylin Library | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asterand today said that its BioSeek subsidiary will screen Amylin Pharmaceuticals' library of compounds to discover peptides with a potential for treating inflammatory conditions.

Under a one-year contract, BioSeek will apply its BioMap predictive human disease models to screen Amylin's library. The new deal builds on earlier similar agreements between the two firms involving peptide screening and related drug discovery activities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.